For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05561387
S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Contact Name:
Study Type:
Oncology - Leukemia/Lymphoma/Myeloma
Study Status:
Open to Accrual
Principal investigator:
Ari Elman, MD
IRB number :
2184196
Study Number:
S2209
Phone:
Fax:
S2302 (Pragmatica - Lung): A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Contact Name:
Study Type:
Oncology - Pulmonary
Study Status:
Open to Accrual
Principal investigator:
David F. Gottlieb, MD
IRB number :
2101334
Study Number:
S2302
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05633602
SGNDV-001: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Contact Name:
Study Type:
Oncology - Genitourinary
Study Status:
Open to Accrual
Principal investigator:
Paul Celano, MD
IRB number :
2134150
Study Number:
SGNDV-001 (G2310)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05911295
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Contact Name:
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Priyanka Mittar, DO
IRB number :
1741169
Study Number:
A011801
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT04457596